Home
overview
Branded pharmaceutical companies face soaring costs of R&D, shrinking pipelines and increased generics competition. In response, questions are raised as to the sustainability of traditional business models, and the leading companies are reviewing their working practices to better mange assets and resources:
  • Transforming operations to improve the development of compounds to drugs
  • Maximizing profitability through integration of lifecycle and portfolio management
  • Shaping business development through collaborative ventures
  • Adapting IP protection to lifecycle stages
The SMi Group’s 2nd Annual Pharmaceutical Portfolio & Lifecycle Management Conference brings together Vice Presidents, Directors and Heads from the pharmaceutical industry to discuss the critical issues surrounding the development of innovative drugs and maintenance of existing assets.
Hear contributions from leading industry experts, including:
  • Dr Hoyoung Huh, Senior Vice President, Business Development & Marketing, Nektar Therapeutics
  • Dr Alan Norris, Director, Strategic Alliances, Gastrointestinal Disease Area, Novartis
  • Dr Sabine Bernotat-Danielowski, Executive Director, Decision Analysis, Daiichi-Sankyo
  • Dr Harsukh Parmer, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy, AstraZeneca
  • Sandy K Tremps, Director, PreClinical Information Services, Merck
  • Dr Alan Raymond, Executive Chairman, Critical Pharmaceuticals
  • Hans Hoogkamer, Head, Life Cycle Portfolio Alignment, Actelion Pharmaceuticals
  • Mike Rea, Chief Executive Officer, IdeaPharma
The SMi Group’s 2nd Annual Pharmaceutical Portfolio & Lifecycle Management Conference provides a unique opportunity to participate in a lively debate and profit from the wealth of knowledge and expertise shared.

Designed to meet industry needs, the conference creates the perfect setting for prolific exchanges of ideas and networking opportunities.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Jonathan Kingslake

Jonathan Kingslake, Consultant, PhFolio, formerly Director of Business Integration, Merck, PhFolio Consultants

9:10 TRANSFORMATION FROM A DRUG DELIVERY TO SPECIALTY BIOPHARMACEUTICAL MODEL

Jennifer Filbey

Jennifer Filbey , Vice President, Business Development , Nektar Therapeutics

  • Industry experience regarding the transition from drug delivery to specialty pharmaceuticals, with Nektar Therapeutics as an example of a successful transition.
  • Critical Success factors
  • Solutions to Overcome Transition Barriers
  • Step-By-Step Management of Transition
  • 9:50 MAXIMISING PERFORMANCE AND VALUE OF THE DISCOVERY AND EARLY DEVELOPMENT PORTFOLIO

    Jonathan Kingslake

    Jonathan Kingslake, Consultant, PhFolio, formerly Director of Business Integration, Merck, PhFolio Consultants

    • Optimizing the portfolio to deliver the company’s strategic objectives
    • Balancing the level of investment with the level of risk
    • Managing the program not just the individual projects
    • Enabling effective and timely decision making

    10:30 Morning Coffee

    11:30 MAXIMIZING PROFITABILITY THROUGH INTEGRATION OF LIFE CYCLE AND PORTFOLIO MANAGEMENT

    Hans Hoogkamer

    Hans Hoogkamer , Head, Lifecycle Portfolio Alignment, Actelion Pharmaceuticals

  • Pharmaceutical companies must continuously develop new drugs to the market
  • The challenge is managing the portfolio to reduce time-to-market and maximize return on investment
  • Effective product development comprises two components: Optimal Life Cycle Management and having right products in your portfolio
  • Integration of results is an added value: enabling companies to proactively manage the portfolio by proactively having key information at multiple levels
  • A link with strategic objectives enables you to measure the alignment of projects in the portfolio with corporate strategy
  • These benefits should result in a reduction of time-to-market with improved quality to maximize profitability
  • 12:10 THE IMPORTANCE OF SUPPLEMENTARY PROTECTION CERTIFICATES IN LIFE CYCLE MANAGEMENT

    Duncan  Curley

    Duncan Curley , Director, Innovate Legal

  • The unique nature of SPCs
  • Recent rulings from the European Court of Justice
  • The European Commission’s decision on the AstraZeneca case
  • Assessing the importance of SPCs
  • 12:50 Networking Lunch

    13:50 PATENT ENFORCEMENT IN EUROPE

    Nigel Stoate

    Nigel Stoate, Partner, Taylor Wessing

    14:30 LICENSING AS A LIFE CYCLE MANAGEMENT TOOL

    John Wilkinson

    John Wilkinson, Partner and Co-Head,, Reed Smith LLP

  • Specific due diligence issues
  • Dealing with specialty pharma
  • Alternatives to licensing
  • 15:10 Afternoon Tea

    15:40 DEVELOPING STRATEGIES FOR PROTECTING IP POTENTIAL IN BIOTECH AND PHARMACEUTICAL INVENTIONS

    Stephen Bennett

    Stephen Bennett, Partner, Lovells

  • Strategies for protecting IP potential: the legal and regulatory framework
  • Protectable subject matter: beyond basic compound strategies
  • Prosecution strategies: what to file when?
  • “Offensive” enforcement strategies: where to sue when?
  • “Defensive” strategies
  • 16:20 MARKET ACCESS FOCUS FOR COMMERCIALISATION

    Brian Lovatt

    Brian Lovatt, Chief Executive Officer & Managing Director, Vision Healthcare

  • Project selection by assessment of health gain
  • Market valuation using curve analysis Pricing and reimbursement strategy
  • Local formulary dossier creation and listing
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Marjan Noor

    Marjan Noor, Partner, Taylor Joynson Garrett

    9:10 DEVELOPING A SPECIALITY PHARMA PORTFOLIO

    John Dawson

    John Dawson, Chief Executive Officer, Alliance Pharmaceuticals

  • Deciding on the balance
  • Becoming a favoured partner
  • Turning ideas into products
  • Getting the financing right
  • Delivering shareholder value
  • 9:50 TRANSFORMING OPERATIONS THROUGH IMPLEMENTATION OF VALUE-DRIVEN CONCEPTS

    Dr Sabine Bernotat-Danielowski

    Dr Sabine Bernotat-Danielowski, Executive Director, Decision Analysis, Daiichi-Sankyo

  • Reviewing procedures to identify bottlenecks and overspending
  • Structural changes improving functionality at discovery, development and commercial interfaces
  • Delivering the value proposition through improved pipeline flow through and late stage success
  • 10:30 Morning Coffee

    11:00 PRODUCT LIFECYCLE MANAGEMENT

    Allistair Booth

    Allistair Booth, Partner, Stringer Saul

  • Outsourcing lead finding and early development to partnering companies with novel technologies
  • Extending knowledge gathering beyond existing in-house capabilities
  • Gauging the value of a partnership beyond the scope of the deal
  • 11:40 PORTFOLIO RISK MANAGEMENT & OPTIMISATION IN PHARMA R&D

    Dr Harsukh Parmer

    Dr Harsukh Parmer, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy, AstraZeneca

  • Productivity (in terms of new NME launches) has dropped off considerably in the last few years
  • R&D spend has continued to escalate
  • Much hyped technologies such as genomics, HTS have failed to deliver productivity improvements
  • Portfolio Risk-Management has been sub-optimal within the industry
  • New operating models and better understanding of human disease processes need to be applied to address these productivity challenges
  • Tools, methods and novel paradigms to improve productivity
  • 12:20 Networking Lunch

    13:50 COMMERCIAL PORTFOLIO STRATEGY

    Mike Rea

    Mike Rea, Chief Executive Officer, IdeaPharma

  • Best practice in pharmaceutical and consumer portfolio planning
  • The commercial imperative and the customer construct
  • Integrating commercial and technical risk analyses
  • Managing multiple brands in the same indication
  • Future mapping and future proofing
  • 14:30 PATENT FILING STRATEGIES AS A DEFENCE AGAINST GENERIC COMPETITION

    Leighton Howard

    Leighton Howard , Managing Director, Generics Web

    Drug patent filing trends – past and present
    Timing of patent filings for optimal benefit
    The future of patents as a viable defence strategy

    15:10 Afternoon Tea

    15:40 QUANTIFYING THE KEY VALUE DRIVERS FOR DEVELOPMENT COMPOUNDS AND LIFE CYCLE MANAGEMENT INITIATIVES

    Gary Johnson

    Gary Johnson, Managing Director, Inpharmation

  • Drivers of pricing leverage: quantifying and valuing clinical benefit, payer sensitivity etc. to each opportunity
  • Drivers of market penetration: quantifying the impact of profile, entry order etc. on market penetration
  • Drivers of market growth: identifying the proven markers of market expansion - increased diagnosis and prescription
  • Drivers of uptake rate: which opportunities will obtain market penetration fastest to deliver greater NPVs
  • 16:20 SCENARIO PLANNING FOR STRATEGIC PORTFOLIO DEVELOPMENT

    Keith Rodgers

    Keith Rodgers, Director, Bodiam Consulting

  • Developing a Sustainable Portfolio through Scenario Planning
  • Scenarios as strategic drivers for change
  • Why scenarios will be critical in the healthcare arena
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Winning Deal Strategies for the Pharmaceutical & Biotechnology Industry
    Workshop

    Winning Deal Strategies for the Pharmaceutical & Biotechnology Industry

    Crowne Plaza Hotel - The City
    26th June 2007
    London, United Kingdom

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.